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ABSTRACT 
Aims: Apocynaceae family is the 5th largest medicinal plant family rich in potent secondary metabolites such as Alkaloids, Cardiac glycosides, 
Terpenoids, irridoid/secoirridoids, flavonoids and Phenolic contents. The present study was aimed to evaluate and compare in-vitro 
antiproliferative activity of three plants of this family. 
Methods: Aerial parts of Carissa carandas Linn. (C), Nerium indicum Mill. (N) and Wrightia tinctoria RBr. (W), were collected  and dried. The 
powdered drugs were extracted in Ethanol (1), 60% Ethanol (2) and Water (3). Estimation of Phytoconstituents performed using standard 
methods. In-vitro cytotoxic activity performed using Sulphorhodamine B (SRB) assay in HepG2, HT29 and SKOV3 human cancer cell lines takin g 
Adriamycin (ADR) as standard. For extracts, GI50 value ≤ 20µg/ml was considered to demonstrate activity.  
Results:  For HepG2 cell line graphs and photomicrographs showed GI50 value as ADR=39.79, C1=2.5, N2=66.3, N3<10 and C2=C3= N1=W1-
3>80. Also TGI for C1>80. The extracts, C1, C2, N1, N2, and N3 were found to possess activity against HepG2.These extracts were screened on 
HT 29 and SKOV3cell lines. The GI50 value observed was<10 for C1, N2, N3 and ADR in HT 29 and <10 for N3 and ADR in SK OV3 ce ll lines. 
Thus it was found that aqueous extract of Nerium indicum (N3) and Ethanolic extract of Carissa carandas (C1) were most cytotoxic extracts 
against all three cell lines. 
Conclusions: our study establishes that Apocynaceae family plants could be an important anticancer lead and could serve as Botanical drug for 
neoplasia. 
Keywords:  Apocynaceae, SRB Assay, Phytoconstituents, Anticancer drug screening models, Hep G2, HT 29, SK-OV3, HCC. 
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1. INTRODUCTION 
Cancer is among the prominent health problem after 
cardiovascular diseases in both developed and developing 
nations. Deaths due to cancer in India are 9% among all 
NCDs [1]. Cancer mortality in India has doubled from 1990 
to 2016. With the advent of 2040, new cancer cases will 
increase by 29.5 million globally [2]. 
Public cancer facilities in India are woefully inadequate, and 
there is large presence of private cancer care facilities [3]. 
Cancer cells reproduce without restraint and colonize other 
tissues. Most cancers develop gradually from increasingly 
aberrant cells. Cancerous growth often depends on defective 
control of cell death, cell differentiation, or both. Cancer cells 
are usually altered in their responses to DNA damage and 
other forms of stress [4, 5]. Carcinogenesis is a result of 
many known and unknown factors biological, chemical, 
physical and environment factors [5, 7]. 
 “Nature is the best healer”. Remedy for all sort of illness is 
surmounted within Mother Nature. Aboriginals of the 
remotest places, disconnected from the central facilities 
survived and surviving even today by their skill of utilizing 
natural resources. Importance of Plants and their 
Phytoconstituents are being recognized globally for their 
pharmaceutical, neutraceutical and other livelihoods. Herbal 
drugs form an inseparable part of the allopathic drug as an 
adjuvant for management of various disorders [8].  
Many important anticancer drugs like, the vinca alkaloids 
(vinblastine, vincristine and vindesine), the 
epipodophyllotoxins (etoposide and teniposide), the taxanes 
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(paclitaxel and docetaxel) and the camptothecin derivatives 
(camptotecin and irinotecan) etc. are derived from plants [9, 
10]. 
“To date the best source of anticancer agents have come 
from toxic plants”. Based on traditional claims, Arrow 
poisons are anticancer [11].  
Apocynaceae family, the fifth valuable medicinal plant family 
among Angiosperms is also called as Dogbane or Arrow 
poisons family [12-20].Traditional uses and potential 
anticancer role of Apocynaceae family plants are widely 
documented [21-24]. 
Development of anticancer drug, pre-clinical and clinical 
trials to compare its benefits to risks ratio with the 
conventional drugs is need of an hour [25-27].This research 
article evaluates the anticancer potential of randomly 
selected three plants of Apocynaceae after an exhaustive 
literature review. Most active aqueous extract of Nerium 
indicum (N3) was further evaluated for its anti-
inflammatory, antimicrobial, immunomodulatory and in 
Hepatic damage induced DEN and CCl4 model used to 
simulate Hepatocellular carcinoma (HCC). This kind of study 
and its inferences are unique of its kind. 
2. MATERIAL AND METHODS 
2.1 Collection and authentication of plant 
Fresh parts of Carissa carandas linn., Nerium indicum mill. 
and Wrightia tinctoria RBr, were collected in the month of 
March-April 2015, from Jhansi region of Bundelkhand 
(Figure 1-3). The Plants were identified and authenticated 
by Dr. Mudailiya, taxonomist NVARI, Jhansi, UP India with 
accession no. 24380, 24381 and 24382 respectively for 
future reference.  
2.2 Plant extracts preparation  
The collected aerial parts of the plants were washed 
thoroughly, shade dried, powdered and sieved Extractive 
yield of plants performed by extracting the plant through 
maceration process. 5g powdered drug added with 50 ml of 
solvents polarity wise taken in 250 ml conical flasks. 
Intermittent shaking of flasks done in 24 hrs maceration 
period. Afterwards filtration, concentration and drying of 
extract done and percentage yield calculated using the 
formula 
%yield= (W1/W2) x 100  
Soxhlet extraction of powdered drug was performed in 
water, 60% Ethanol and Ethanol separately [26, 27].The 
extracts were filtered, concentrated to dryness in Rotary 
evaporator and Lyophilizer. Percentage yield calculated and 
stored in deep freezer for future use. 
2.3 Phytochemical study   
Qualitative estimation of Phytoconstituents performed 
according to standard method [28- 30]. 
2.4 Anticancer screening  
For in vitro study, the cancer cell line culture (Hep G2, HT 29 
and SK OV3) and media used in this study and standard drug 
Adriamycin (ADR) were arranged at Advanced Centre for 
Treatment Research and Education in Cancer (ACTREC), 
Kharghar, Navi Mumbai. Other studies were conducted at 
Bundelkhand University, Jhansi and Pinnacle Biomedical 
research institute, Bhopal. 
In vitro Study 
SRB Assay procedure as per ACDSF (ACTREC), Mumbai [31, 
32].  
The cell lines were grown in RPMI 1640 medium containing 
10% fetal bovine serum and 2 mM L-glutamine. Cells were 
inoculated into 96 well microtiter plates in 100 µL at plating 
densities, depending on the doubling time of individual cell 
lines. After cell inoculation, the microtiter plates were 
incubated at 37°C, 5% CO2, 95% air and 100% relative 
humidity for 24 h prior to addition of experimental drugs.  
Extracts were solubilized in dimethyl sulfoxide at 100mg/ml 
and diluted to 1mg/ml using water and stored frozen prior 
to use. At the time of drug addition, an aliquote of frozen 
concentrate (1mg/ml) was thawed and diluted to 100 μg/ml, 
200 μg/ml, 400 μg/ml and 800 μg/ml with complete 
medium containing test article. Aliquots of 10 µl of these 
different drug dilutions were added to the appropriate 
microtiter wells already containing 90 µl of medium, 
resulting in the required final drug concentrations i.e.10 
μg/ml, 20 μg/ml, 40 μg/ml, 80 μg/ml. then plates were 
incubated for 48 hours and assay was terminated by the 
addition of cold TCA. Cells were fixed in situ by the gentle 
addition of 50 µl of cold 30 % (w/v) TCA (final 
concentration, 10 % TCA) and incubated for 60 minutes at 
4°C. The supernatant was discarded; the plates were washed 
five times with tap water and air dried. Sulforhodamine B 
solution (50 µl) at 0.4 % (w/v) in 1 % acetic acid was added 
to each of the wells, and plates were incubated for 20 
minutes at room temperature. After staining, unbound dye 
was recovered and the residual dye was removed by 
washing five times with 1 % acetic acid. The plates were air 
dried. Bound stain was subsequently eluted with 10 mM 
trizma base, and the absorbance was read on a plate reader 
at a wavelength of 540 nm with 690 nm reference 
wavelength.  
Percent growth was calculated on a plate-by-plate basis for 
test wells relative to control wells. Percent Growth was 
expressed as the ratio of average absorbance of the test well 
to the average absorbance of the control wells * 100.  
Using the six absorbance measurements [time zero (Tz), 
control growth (C), and test growth in the presence of drug 
at the four concentration levels (Ti)]; the percentage growth 
was calculated at each of the drug concentration levels. 
Percentage growth inhibition was calculated as:  
[Ti/C] x 100 % 
Statistical analysis of Data 
All values are expressed as Mean ± SD (mean and standard 
deviation) of three replicated experiments. The analysis was 
performed using Microsoft excel 2007 and SPSS statistical 
package for WINDOWS (version 16.0; SPSS, Inc., Chicago, IL, 
USA).   
3. RESULTS AND DISCUSSION 
Extraction 
Extraction of phytoconstituents performed and obtained 
percentage yield (Table 1) 
 In Vitro Anticancer activity 
Results are shown in Table 4a-4b and 5a-5b. 
Photomicrograph of the cells predicts the cell density 
(Figure 4-29). Adriamycin was taken as standard to validate 
the studies. Extracts of Wrightia tinctoria (W1, W2 and W3) 
was found totally inactive in Hep G2 and SK OV3 cell lines. 
Other extracts except C1 and N3 tested did not show any 
significant activity.  
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Index of antiproliferative activity was calculated from graph 
and expressed in terms of LC50, GI50 and TGI. Plant extract 
with GI 50 value ≤ 20µg/ml is considered to demonstrate 
activity. In Hep G2 cell line the order of activity was as: C1 
(2.5)> N3 (<10)> N2 (66.3)> C2=C3 (>80). Antiproliferative 
effect of these extracts in HT 29 has GI 50 value as C1, N2, 
N3<10 and N3 is the highly active with GI50<10 µg/ml in SK 
OV3 cell line. Thus Aqueous extract of Nerium indicum Mill. 
(N3) is most active extract in all three cancer cell lines. The 
Concentration of drug causing total inhibition of cell growth 
(TGI) value <10 for N3 and 36.8 for C1 in HT 29 cell line. The 
Concentration of drug causing 50% cell kill (LC50) value for 
N3 is 56.8 and it is Non-evaluable in other extracts.
 
Table 1 Extractive Yield 
Solvents with decreasing 
polarity 
% yield w/w= W1/W2x100 
Carissa Nerium Wrightia 
n-Hexane 1.182 3.814 1.631 
Petroleum Ether 0.64 4.21 3.32 
Ethyl Acetate 0.77 1.45 2.81 
chloroform 4.43 1.439 2.50 
Ethanol 7.27 10.86 7.86  
Water 11.28 3.78 5.11 
 
Table 2 Qualitative phytoconstituents Analysis 
S.NO. Test Carissa carandas  Nerium indicum Wrightia tinctoria 
Tests  Extracts C1 C2 C3 N1 N2 N3 W1 W2 W3 
Glycosides-
cardiac/anthraquinone 
Borntrager's test +++ +++ +++ ++ ++ +/- + + + 
Saponins Foam test ++ ++ ++ - - ++ ++ ++ ++ 
Oils and fat Spot test + + + +++ ++ + + + + 
Phlobatannins/ 
Chalcones 
HCl test/spot test - - - - - - + - - 
Flavonoids AlCl3 test/ alkaline reagent 
test/lead acetate test 
+++ +++ +++ +++ +++ +++ +++ +++ +++ 
Tannins/Phenolic 
compound 
FeCl3 test/ Lead acetate test +++ +++ +++ +++ +++ +++ +++ +++ +++ 
Alkaloids wagner’s  test/mayer’s 
test/hagers/dragendorffs 
++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ 
Protein/Amino acids ninhydrin/ xanthoproteic ++ ++ ++ ++ ++ ++ ++ ++ ++ 
Steroids salkowski’s test/ 
Liebermann buchard 
++ + - - - - + - - 
Phytosterols sulphuric acid test  + - - + - - + - - 
Carbohydrates/ sugar molish’s test/ Benedict’s test + + - + - + + + + 
Coumarins  fluorescens test + - - + - - + -  
 
Table 3a Percent control growth in Hep G2 cancer cell line 
s 
a 
m
 p
 l
e
 Human Hepatoma Cell Line Hep-G2 
% Control Growth 
Drug Concentrations (µg/ml) 
Experiment 1 Experiment 2 Experiment 3 Average Values 
10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
C1 51.3 46.5 28.7 23.2 44.8 37.4 24.9 8.4 48.9 48.3 27.4 19.7 48.3 44.1 27.0 17.1 
C2 134.
9 
140 144.
6 
133.
9 
132.
6 
140.
1 
141.
3 
136.
5 
125.
8 
137.
4 
137.
8 
155.
2 
131.
1 
139.
2 
141.
2 
141.
9 
C3 138.
5 
155.
1 
152.
3 
145.
8 
136.
8 
139.
2 
141.
1 
151.
5 
130.
0 
147.
2 
146.
5 
159.
4 
135.
1 
147.
2 
146.
6 
152.
2 
N1 132.
5 
143.
5 
151.
5 
136.
0 
130.
0 
150.
8 
146.
7 
144.
9 
123.
1 
133.
4 
143.
4 
133.
9 
128.
5 
142.
6 
147.
2 
138.
3 
N2 76.2 59.1 68.1 42.0 70.0 59.2 63.8 42.0 80.2 59.6 60.2 48.6 75.5 59.3 64.0 44.2 
N3 14.8 22.3 17.5 23.5 15.8 20.2 15.0 15.0 20.7 15.1 3.9 5.9 17.1 19.2 12.1 14.8 
WI 129.
2 
135.
2 
143.
0 
123.
8 
134.
7 
139.
3 
133.
4 
135.
2 
136.
1 
146.
2 
120.
7 
119.
9 
133.
3 
140.
2 
132.
4 
126.
3 
W2 129.
8 
141.
0 
125.
1 
123.
4 
140.
7 
144.
1 
127.
3 
98.6 143.
2 
159.
3 
140.
2 
98.3 137.
9 
148.
1 
130.
9 
106.
8 
W3 135.
6 
164.
6 
176.
9 
177.
5 
151.
4 
158.
3 
168.
2 
172.
0 
136.
1 
160.
0 
158.
5 
160.
1 
141.
0 
161.
0 
167.
9 
169.
9 
AD
R 
180.
0 
134.
3 
63.6 -27.7 67.2 139.
9 
-9.5 -38.7 123.
3 
105.
8 
-39.4 -32.3 123.
5 
126.
7 
4.9 -32.9 
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Table 4a Percent control growth in HT 29 cancer cell line 
  Human Colon Cancer Cell Line HT-29,   % Control Growth 
   Drug Concentrations (µg/ml) 
  Experiment 1 Experiment 2 Experiment 3 Average Values 
  10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
C
1
 
2
0
.2
 
1
4
.7
 
5
.7
 
-4
2.
5 
2
2
.4
 
1
4
.6
 
4
.8
 
-5
3.
4 
2
0
.1
 
1
5
.6
 
4
.9
 
-3
5
.4
 
2
0
.
9
 
1
4
.
9
 
5
.
1
 
 
-43
.7  
C
2
 
1
0
7
.1
 
1
0
8
.9
 
11
5.
4 
11
2.
7 
1
0
4
.2
 
10
6.
1 
10
6.
8 
10
6.
7 
1
0
6
.4
 
1
1
7
.5
 
1
1
5
.8
 
1
0
9
.3
 
1
0
5
.9
 
1
1
0
.8
 
1
1
2
.7
 
1
0
9
.6
 
N
1
 
1
0
0
.8
 
1
0
6
.7
 
12
3.
9 
13
1.9
 
1
0
6
.0
 
10
6.
5 
11
9.
4 
12
0.
3 
1
0
5
.7
 
1
1
8
.1
 
1
1
7
.7
 
1
2
1
.5
 
1
0
4
.2
 
1
1
0
.5
 
1
2
0
.3
 
1
2
4
.6
 
N
2
 
3
7
.0
 
2
3
.0
 
2
8
.2
 
2
0
.3
 
3
4
.1
 
2
3
.8
 
2
9
.2
 
1
8
.6
 
3
1
.2
 
2
4
.2
 
2
5
.
1
 
1
8
.
5
 
3
4
.
1
 
2
3
.
7
 
2
7
.
5
 
1
9
.
1
 
N
3
 
6
.
5
 
-3
4
.3
 
-5
0.
4 
-5
3.
9 
3
.
6
 
-3
5.
1 
-4
8.
2 
-5
1.
4 
-1
1
.9
 
-5
3
.2
 
-6
9
.4
 
-6
0
.5
 
-
0
.
6
 
-
4
0
.9
 
-5
6
.0
 
-5
5
.3
 
A
D
R 
-
2
.9
 
-
6
.1
 
-9
.1
 
-1
1.
3 
1
.
6
 
-9
.2
 
-3
.2
 
-9
.1
 
-
6
.3
 
-1
8
.3
 
-1
8
.3
 
-
8
.
2
 
-
2
.
5
 
-
1
1
.
2
 
-1
0
.2
 
-
9
.
5 
 
 
Table 5a Percent control growth in SK-OV3 cancer cell line 
 
Human Ovarian Cancer Cell Line  SK-OV-3, % Control Growth 
   Drug Concentrations (µg/ml) 
sampl
e  
Experiment 1 Experiment 2 Experiment 3 Average Values 
  10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
C1 
93.2 66.7 65.4 63.2 83.7 68.0 62.0 72.1 87.0 
103.
6 
111.
4 
69.1 88.0 79.4 79.6 68.1 
C2 104.
0 
104.
6 
109.
5 
111.
8 
116.
6 
132.
8 
121.
7 
145.
0 
130.
2 
122.
7 
143.
4 
123.
3 
116.
9 
120.
1 
124.
9 
126.
7 
N1 106.
2 
101.
2 
113.
5 
122.
0 
122.
0 
113.
9 
130.
1 
134.
7 
135.
9 
119.
8 
131.
4 
136.
9 
121.
4 
111.
6 
125.
0 
131.
2 
N2 103.
7 
77.4 94.8 71.7 
101.
3 
82.4 92.4 77.5 
106.
9 
110.
9 
122.
4 
93.3 
103.
9 
90.2 
103.
2 
80.8 
N3 76.0 62.2 65.4 58.6 70.0 59.5 54.1 75.2 70.1 77.3 94.5 68.5 72.0 66.3 71.3 67.4 
ADR -
39.8 
-
47.4 
-
44.2 
-
31.4 
-
58.6 
-
60.6 
-
61.3 
-
40.7 
-
58.2 
-
60.1 
-
55.3 
-
23.7 
-
52.2 
-
56.0 
-
53.6 
-
31.9 
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Table 6b Percent control growth in Hep G2 cancer cell line 
 Human Hepatoma Cell Line Hep G2- % Growth 
 Drug concentrations (µg/ml) calculated from graph 
 C1 C2 C3 N1 N2 N3 W1 W2 W3 ADR 
LC 50 NE NE NE NE NE NE NE NE NE 80.9 
TGI >80 NE NE NE NE NE NE NE NE 60.3 
GI50* 2.5 >80 >80 >80 66.3 <10 >80 >80 >80 39.79 
 
Table 5b-7b Percent control growth in HT 29 and SK-OV3 cancer cell line 
 Human Cancer Cell Line % Growth 
 Drug concentrations (µg/ml) calculated from graph 
 Human Colon Cancer Cell Line- HT 29 Human Ovarian Cell Lines SK OV 3 
 C1 C2 N1 N2 N3 ADR C1 C2 N1 N2 N3 ADR 
LC 50 NE NE NE NE 56.8 NE NE NE NE NE NE 32.6 
TGI 36.8 NE NE NE <10 NE NE NE NE NE NE NE 
GI50* <10 >80 >80 <10 <10 <10 >80 >80 >80 >80 <10 <10 
** LC50 = Concentration of drug causing 50% cell kill.  GI50 = Concentration of drug causing 50% inhibition of cell growth. TGI = Concentration 
of drug causing total inhibition of cell growth. ADR = Adriamycin, Positive control compound. NE = Non- evaluable data. Experiment needs to be 
repeated using different set of drug concentrations. GI50 value of ≤ 10^-6 molar (i.e. 1 µmolar) or ≤ 10µg/ml is considered to demonstrate 
activity in case of pure compounds. For extracts, GI50 value ≤ 20µg/ml is considered to demonstrate activity. Yellow highlighted test values 
under GI50 column indicate activity 
 
   
Figure 1 Carissa carandas Linn. (C)              Figure 2 Nerium indicum Mill.(N)                  Figure 3 Wrightia tinctoria R.Br.(W) 
   
 Figure 4 HEP G2 Control                                Figure 5 HEP - G2 positive control                Figure 6 HEP - G2 C1                                                                                                              
   
Figure 7 HEP G2 C2                                         Figure 8: HEP G2 C3                                      Figure 9 HEP - G2 N1                                                                                                                                                                                                     
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Figure 10 HEP G2 N2                                      Figure 11 HEP - G2 N3                           Figure 12 HEP - G2 W1                                                                                                     
   
Figure 13 HEP - G2 W2                                 Figure 14 HEP - G2 W3   
   
Figure 17 HT 29 C1                                         Figure 18 HT 29 C2                        Figure 19 HT 29 N1                                                                                                                                                                                                                                   
   
Figure 20 HT 29 N2                                           Figure 22 HT 29 N3                                   Figure 15 HT 29 Positive Control             
   
Figure 16 HT 29 Control                  Figure 23 SK OV3 Positive control      Figure 24 SK OV3 Control                    
     
            Figure 25 SK OV3 C1                                  Figure 26 SK OV3 C2                                Figure 27 SK OV3 N1 
  
         Figure 28 SK OV3 N2                                  Figure 29 SK OV3 N3    
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Figure 30 Growth Curve of various cell lines 
 
CONCLUSION  
Since three decades a vast majority of plants are being 
screened for their cytotoxic actions. A plethora of preclinical 
data is available in reviews, research and reports. Abundance 
of traditional knowledge from herb practitioners (tribal, 
villagers and Ayurvedachaarya etc.) has made possible to 
screen cytotoxic plants [33, 34]. These successes have 
resulted from testing of some extracts or derived 
compounds, with little regard to the possible metabolism of 
constituents in vivo or to activities other than cytotoxicity 
that might reduce carcinogenesis. In vitro assays are easy 
tools and provide large data at time. This study is the re-
investigation of extracts based on their traditional claims to 
possess cytotoxicity. Therefore this is a novel approach to 
complement standard cytotoxic screening procedures for 
research on previously uninvestigated material. The Results 
clearly indicate that Carissa carandas, Nerium indicum and 
Wrightia Tinctoria belonging to Apocynaceae family could be 
an important lead in cancer remediation. Thus, the current 
work clearly indicates that carvacrol could be a potent anti-
tumor molecule Antineoplastic mechanism of these plants 
should be further studied for its possible mechanism and 
through different models in vivo models. Isolation of active 
phytoconstituents and their separate screening would 
further validate the 
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